A cogent example of this binary response is in the mobilization of co-stimulatory and co-inhibitory signaling in regulating the strength ... costimulatory molecule CD28 which is countered by CTLA-4.

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the Mesothelioma ...

CTLA-4, cytotoxic T-lymphocyte associated protein 4; TIGIT, T-cell immunoglobulin and ITIM domain; LAG-3, lymphocyte activation gene 3. By FigDraw. The molecular pathogenesis of T cell-associated ...

During embryonic development, the intestine of the Drosophila fly divides into distinct chambers thanks to the formation of ...

This important study provides solid evidence that glucosylceramide synthase (GlcT), a rate-limiting enzyme for glycosphingolipid (GSL) production, plays a role in the differentiation of intestinal ...

The mainstay of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) remains a combination of androgen deprivation therapy along with standard-of-care androgen receptors ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...